Millipore Sigma Vibrant Logo

196876 BAY 41-2272 - CAS 256376-24-6 - Calbiochem

A cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase).

BAY 41-2272 - CAS 256376-24-6 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine

Primary Target: Soluble guanylate cyclase
View This Product on Sigma-Aldrich
196876
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
256376-24-6C₂₀H₁₇FN₆

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
196876-5MGCN
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 5 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases.
      Catalogue Number196876
      Brand Family Calbiochem®
      Synonyms5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
      References
      ReferencesBoerrigter, G., et al. 2003. Circulation 107, 686.
      Kalsi, J.S., et al. 2003. J Urol. 169, 761.
      Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
      Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
      Stasch, J.P., et al. 2001. Nature 410, 212.
      Product Information
      CAS number256376-24-6
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₂₀H₁₇FN₆
      Chemical formulaC₂₀H₁₇FN₆
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetSoluble guanylate cyclase
      Primary Target IC<sub>50</sub>304 nM inhibiting phenylephrine-induced constriction of rabbit aortic rings; 36 nM in blocking collagen-induced aggregation of human platelets
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      196876-5MGCN 04055977206593

      Documentation

      BAY 41-2272 - CAS 256376-24-6 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      BAY 41-2272 - CAS 256376-24-6 - Calbiochem Certificates of Analysis

      TitleLot Number
      196876

      References

      Reference overview
      Boerrigter, G., et al. 2003. Circulation 107, 686.
      Kalsi, J.S., et al. 2003. J Urol. 169, 761.
      Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
      Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
      Stasch, J.P., et al. 2001. Nature 410, 212.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-April-2011 RFH
      Synonyms5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
      DescriptionA cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases.
      FormWhite solid
      CAS number256376-24-6
      Chemical formulaC₂₀H₁₇FN₆
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (10 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesBoerrigter, G., et al. 2003. Circulation 107, 686.
      Kalsi, J.S., et al. 2003. J Urol. 169, 761.
      Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
      Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
      Stasch, J.P., et al. 2001. Nature 410, 212.